In vivo studies reveal that after the establishment of palpable tumors, treatment with CAY10566 at a dose of 2.5 mg/kg administered orally twice daily exhibits a more pronounced effect on Akt-driven tumors compared to Ras-driven tumors. The mean tumor volume, relative to untreated tumors by day 13 or 14 post-therapy, is significantly lower in the Akt-driven tumor group (0.5±0.04) than in the Ras-driven tumor group (0.67±0.05), with a P-value of 0.01 for the comparison between Ras and Akt-driven tumors as determined by a two-tailed t-test^[4].

Additionally, CAY10566 concentration-dependently reduces the proliferation of Swiss 3T3 cells over 24 hours, with a concentration range of 0.0001-10 μM^[3].